Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025.

Company Presentation Details:

Date: Monday, January 13, 2025
Time: 9:45-10:25 AM Pacific Time (12:45-1:25 PM Eastern Time)
Webcast: Register here

Presenter: Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals

A live audio webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

Staff

Recent Posts

TEDCO’s Maryland Innovation Initiative Announces FY2025 Technology Assessment Awards

Over $1 million awarded to 7 university projects  COLUMBIA, Md., April 24, 2025 /PRNewswire/ -- TEDCO,…

5 hours ago

RS and Siemens are paving the way to Industry 5.0 with I/O

RS offers Siemens IP6X distributed I/O systems engineered to satisfy organizations' ever-increasing demand for actionable…

5 hours ago

INAUGURAL FUTURE WAY FORWARD CONFERENCE INVITES AMERICA TO COME TOGETHER — FOR REAL AND FOR GOOD

Physician turned founder creates new opportunity for collaboration, growth, and positive social changeNASHVILLE, Tenn., April…

5 hours ago

KONZA National Network Joins Missouri eLTSS Project Phase 2 to Advance Person-Centered Care for Individuals with IDD

TOPEKA, Kan., April 24, 2025 /PRNewswire/ -- KONZA National Network is proud to announce its partnership…

5 hours ago

ApolloMD Partners with Cleo Health to Transform Emergency Medicine Documentation Through AI Innovation

ATLANTA, April 24, 2025 /PRNewswire/ -- ApolloMD, one of the nation's leading physician services organizations, today…

5 hours ago

BISSELL Takes on Shedding Season with its Most Powerful Stick Vacuum Yet

PowerClean® FurFinder™ and PowerClean® FurGuard™ cordless stick vacuums find and powerfully capture pet hair and…

5 hours ago